Could neoadjuvant chemotherapy increase postoperative complication risk of laparoscopic total gastrectomy? A mono-institutional propensity score-matched study in China

Table 1 Baseline characteristics of laparoscopic total gastrectomy after neoadjuvant chemotherapy group and laparoscopic total gastrectomy group before propensity-score matching

Clinical characteristic	NC-LTG group (n = 92)	LTG group (n = 381)	P value
Sex			0.109
Male	68	310
Female	24	71
Age (yr, mean ± SD)	58.87 ± 10.28	59.85 ± 11.40	0.452
BMI (kg/m2, mean ± SD)	23.03 ± 2.97	23.79 ± 3.65	0.065
History of abdominal surgery			0.368
Yes	17	56
No	75	325
ASA grade			0.023
I	10	3
II	72	336
III	10	42
Tumor diameter, cm (median, IQR)	4.00 (3.00-6.37)	5.00 (3.00-6.50)	0.108
pT			0.433
T0-T1	12	63
T2	15	38
T3	52	206
T4	13	74
pN			0.129
N0	36	127
N1	15	54
N2	18	73
N3	23	127
pTNM			0.600
0-I	20	80
II	28	105
III	44	196
Differentiation			0.829
Well/moderate	44	187
Poor/undifferentiated	48	194
Nerve invasion			0.150
Yes	29	151
No	63	230
Vascular invasion			0.220
Yes	28	142
No	64	239

NC-LTG: Laparoscopic total gastrectomy after neoadjuvant chemotherapy; LTG: Laparoscopic total gastrectomy; BMI: Body mass index; ASA: American Society of Anesthesiologists; IQR: Interquartile range; TNM: Tumor-node-metastasis.